[HTML][HTML] Experimental and clinical treatment of Chagas disease: a review

PAS Junior, I Molina, SMF Murta… - The American journal …, 2017 - ncbi.nlm.nih.gov
Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a
broad range of triatomines and mammalian species, including man. It afflicts 8 million …

[HTML][HTML] Advances in the treatment of Chagas disease: Promising new drugs, plants and targets

P García-Huertas, N Cardona-Castro - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Chagas disease, caused by Trypanosoma cruzi, is treated with only two drugs;
benznidazole and nifurtimox. These drugs have some disadvantages, including their …

Current drug therapy and pharmaceutical challenges for Chagas disease

J Bermudez, C Davies, A Simonazzi, JP Real, S Palma - Acta tropica, 2016 - Elsevier
One of the most significant health problems in the American continent in terms of human
health, and socioeconomic impact is Chagas disease, caused by the protozoan parasite …

[HTML][HTML] Current trends in the pharmacological management of Chagas disease

V Ribeiro, N Dias, T Paiva, L Hagström-Bex… - International Journal for …, 2020 - Elsevier
Chagas disease (CD) is a tropical neglected illness, affecting mainly populations of low
socioeconomic status in Latin America. An estimated 6 to 8 million people worldwide are …

CYP51 as drug targets for fungi and protozoan parasites: past, present and future

GI Lepesheva, L Friggeri, MR Waterman - Parasitology, 2018 - cambridge.org
The efficiency of treatment of human infections with the unicellular eukaryotic pathogens
such as fungi and protozoa remains deeply unsatisfactory. For example, the mortality rates …

Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial

MJ Pinazo, C Forsyth, I Losada, ET Esteban… - The Lancet Infectious …, 2024 - thelancet.com
Background More than six million people worldwide, particularly in vulnerable communities
in Latin America, are infected with Trypanosoma cruzi, the causative agent of Chagas …

[HTML][HTML] Therapeutic Potential of Marine-Derived Cyclic Peptides as Antiparasitic Agents

R Ribeiro, L Costa, E Pinto, E Sousa, C Fernandes - Marine Drugs, 2023 - mdpi.com
Parasitic diseases still compromise human health. Some of the currently available
therapeutic drugs have limitations considering their adverse effects, questionable efficacy …

[HTML][HTML] Infecciones por parásitos más frecuentes y su manejo

BW Apt - Revista Médica Clínica Las Condes, 2014 - Elsevier
Las enfermedades parasitarias constituyen un problema de salud pública por su alta
frecuencia en países en vías de desarrollo y por la presencia en países desarrollados …

Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs

R Madigan, S Majoy, K Ritter… - Journal of the …, 2019 - Am Vet Med Assoc
OBJECTIVE To evaluate clinical, serologic, parasitological, and histologic outcomes of dogs
with naturally occurring Trypanosoma cruzi infection treated for 12 months with amiodarone …

Stairway to heaven or hell? Perspectives and limitations of Chagas disease chemotherapy

K Salomao… - Current Topics in …, 2016 - ingentaconnect.com
In this review, we intend to provide a general view of the evolution of experimental studies in
the area of chemotherapy for Chagas disease. We can follow the process of drug …